Ibsium is made using a strain of Saccharomyces cerevisiae, which is a species of yeast and has been approved to make the claim: ‘helps to reduce abdominal pain and discomfort associated with IBS’ in Canada by the CHA.
The health claims approval followed the recent publication of a study in the journal Digestive and Liver Disease.
Ibsium is also known as Lynside Pro in other countries and is claimed to reduce abdominal pain and discomfort in individuals with IBS.
Two clinical studies on 600 volunteers with IBS were carried out by independent gastroenterologists and the firm. Another consumer study, in collaboration with doctors and 1,160 IBS sufferers, was also carried out by Lesaffre.
Positive impact on sales
Lesaffre global marketing director Sandrine Cuisenier says: “With millions of people worldwide affected by IBS, many of them unsatisfied with their current treatment, this claim approval will definitely have a positive impact on sales.
“It strengthens the position of our customers on the market by allowing end-users to better grasp the real benefits that Ibsium could have on their quality of life.”